


## Selecting Appropriate Patients for Tresiba® (Insulin Degludec) 100 units/ml Treatment

This Applies To Patients Aged Over 18 Years With Type 1 And Type 2 Diabetes Who Are Taking Basal-Bolus Insulin Regimen – Consultant Only Initiation



### Review

Since Tresiba® (insulin degludec) is more expensive than Lantus® (insulin glargine) it is important to establish that it is delivering the improvement required of it. After a 3 month trial the specialist team will assess the response to Tresiba® and decide whether it is to continue.

If the reason for using it was to reduce nocturnal hypoglycaemia, the frequency and severity of hypoglycaemia must be documented before starting and after 3 months. If there has been no significant improvement then Tresiba® should be stopped.

If the reason for prescribing it was to address variably high fasting glucose concentrations, the patient's glucose log (preferably on a memory meter) before and after 3 months should be scrutinised and if there has been no significant improvement then Tresiba® should be stopped.

If failure to meet HbA1c target was part of the rationale to start Tresiba®, then a repeat measurement after 3 months should be compared with the initial value and a failure to improve should normally result in stopping Tresiba®.